Navigation Links
Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
Date:9/10/2013

p>Boehringer Ingelheim has a comprehensive interferon-free clinical trial program, HCVerso®, which includes three pivotal Phase 3 studies. The HCVerso® studies aim to enroll approximately 1,100 treatment-naive and experienced HCV genotype-1b (GT-1b) patients, including those who are interferon eligible or ineligible, and those with compensated liver cirrhosis.

For more information regarding the trial, please visit www.clinicaltrials.gov.

About Boehringer Ingelheim in Hepatitis C Virus (HCV)
In partnership with the scientific community, our clinical trial program is rigorously designed to find answers to the challenges that HCV patients face, including those who are the most difficult to treat. Our pivotal HCV clinical trials for faldaprevir and deleobuvir are comprised of two multi-trial programs, STARTVerso® and HCVerso®.

Faldaprevir, also known as BI 201335, is an investigational, oral protease inhibitor that is specifically designed to target viral replication in the liver. Boehringer Ingelheim is developing faldaprevir as a core component of both interferon-based and interferon-free hepatitis C treatment regimens. STARTVerso®1 is the first of an ongoing multi-study Phase 3 trial program that is evaluating faldaprevir combined with PegIFN/RBV. Three additional trials in treatment-naive, treatment-experienced and HIV co-infected patients with chronic genotype-1 HCV are near clinical completion. Deleobuvir, also known as BI 207127, is an investigational NS5B non-nucleoside polymerase inhibitor that has shown the potential to eliminate interferon from HCV treatment when combined in a regimen with faldaprevir and RBV. Phase 2 trials of this interferon-free regimen have been completed and Phase 3 HCVerso® trials investigating this regimen are now underway. As part of our long-term commitment to HCV, the company is exploring other combinations o
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
2. Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
3. Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
4. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
5. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
6. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
7. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
8. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
9. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
10. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
11. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... is pleased to announce the signing of a reseller ... CIVCO,s Body Pro-Lok to its customers. Introduced in 2008 ... worldwide, Body Pro-Lok excels as a modular base for ... (Logo: http://photos.prnewswire.com/prnh/20110419/AQ85801LOGO ) ...
... July 29, 2011 Argos Therapeutics, Inc. today announced that ... the U.S. Securities and Exchange Commission (SEC) relating to a ... All shares of the common stock to be sold in ... Lazard Capital Markets LLC and Canaccord Genuity Inc. are acting ...
Cached Medicine Technology:Varian Medical Systems to Offer CIVCO Medical Solutions' Body Pro-Lok™ for SBRT 2Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering 2
(Date:7/9/2014)... that sudden, acute episodes of low back pain are ... air pressure, wind direction and precipitation. Findings published in ... the American College of Rheumatology (ACR), indicate that the ... wind speed or wind gusts, but was not clinically ... (WHO) nearly everyone experiences low back pain at some ...
(Date:7/9/2014)... Susan Wakulich was told she had an aneurysm, she figured ... her. , "I was devastated," said Wakulich, who is 56 ... this was a serious diagnosis. Then I met Dr. Bernard ... a less invasive procedure. It was something I didn,t even ... a multi-center U.S. clinical trial to evaluate the safety and ...
(Date:7/9/2014)... into the metabolism of stromal support cells and immune ... these cell types in the development of diseases ... and cancer. That was the conclusion of a review ... the leading journal Nature . , Prof. Peter ... call. The metabolism of cancer cells has been examined ...
(Date:7/9/2014)... from The Miriam Hospital have found that people ... also depressed have difficulty sticking to a pulmonary ... for women, and screening and brief treatment of ... The study and its findings are published in ... Chronic obstructive pulmonary disease is a common and ...
(Date:7/9/2014)... Montefiore Medical Center and the Albert ... present new findings at the Alzheimer,s Association International Conference ... Copenhagen, Denmark. Data from the four abstracts will focus ... to mild cognitive impairment and dementia. The research is ... in 1980 to examine healthy brain aging as well ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Wake-up call for more research into cell metabolism 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3
... of Nationwide Awareness Campaign - KENILWORTH, N.J., March ... SGP ), maker of the non-drowsy ... allergy sufferer and NASCAR driver Carl Edwards to ... News Release, go to: http://www.prnewswire.com/mnr/claritin/37512/ "Drowsy driving ...
... DENVER, March 18 St. Joseph,s Hospital in Marshfield, ... Medical Technologies, VersaRad CR radiography system. These units ... as for St. Joe,s Diagnostic Imaging services. St. Joseph,s ... of the Marshfield medical complex serving Wisconsin and the ...
... Northern California Chapter of the National MS SocietyMOUNTAIN VIEW, Calif., ... special donation program to coincide with MS Awareness ... a cure for multiple sclerosis. For each sale of a ... 2009, Presto Services Inc. will donate 5% of the retail ...
... TO ARMS 2009 EDITION" is a new documentary ... traces the controversial Anthrax Vaccine Immunization Program ( AVIP ... Through the personal invitation of Rick and Rozene ... Baristo Rd., Palm Springs, CA, the documentary feature had ...
... equipment to be acquired as part of purchaseMOUNTAIN VIEW, ... Los Gatos Town Council last evening, El Camino Hospital ... Camino Hospital had signed agreements that will allow an ... Los Gatos acquisition. The agreements will allow El ...
... March 17 Standard & Poor,s Rating Services (S&P) ... ,B, on Huntsman Corporation,s (NYSE: HUN ) ... that its operations are sound and that its liquidity ... Huntsman has met the challenging operating environment by ...
Cached Medicine News:Health News:Video: CLARITIN Partners with NASCAR Driver Carl Edwards to Educate Motorists on the Importance of Being Clear to Drive(SM) 2Health News:Video: CLARITIN Partners with NASCAR Driver Carl Edwards to Educate Motorists on the Importance of Being Clear to Drive(SM) 3Health News:Fischer Medical Announces Multi-System VersaRad Installation at St. Joseph's Hospital in Marshfield, WI 2Health News:Presto Announces Donation Program to Help Find the Cure for Multiple Sclerosis 2Health News:Presto Announces Donation Program to Help Find the Cure for Multiple Sclerosis 3Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 2Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 3Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 4Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 5Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 6Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 7Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 8Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 9Health News:Scott Miller and Company Premieres "A CALL TO ARMS 2009 EDITION" at the Camelot Theaters in Palm Springs 10Health News:Parties in Los Gatos Hospital Acquisition Agree on Terms Allowing El Camino Hospital an Early Close of Escrow 2Health News:Parties in Los Gatos Hospital Acquisition Agree on Terms Allowing El Camino Hospital an Early Close of Escrow 3Health News:Huntsman Responds to S&P Action 2Health News:Huntsman Responds to S&P Action 3
Bone Curette, 180 mm...
Kevorkian Collector Endocervical Curette is a stainless-steel curette with rounded tip....
Kevorkian Endocervical Curette is a stainless-steel curette with a basket. It is narrow tipped for sampling without dilation....
...
Medicine Products: